Balance Sheet

Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Sunshine Biopharma (SBFM) Short-Term Debt issuances (2020)

Sunshine Biopharma filings provide 1 years of Short-Term Debt issuances readings, the most recent being $33607.0 for Q4 2020.

On a quarterly basis, Short-Term Debt issuances changed N/A to $33607.0 in Q4 2020 year-over-year; TTM through Dec 2021 was $36607.0, a N/A change, with the full-year FY2021 number at $61500.0, up 51.45% from a year prior.
Short-Term Debt issuances hit $33607.0 in Q4 2020 for Sunshine Biopharma, up from $3000.0 in the prior quarter.
In the past five years, Short-Term Debt issuances ranged from a high of $33607.0 in Q4 2020 to a low of $3000.0 in Q3 2020.